PMA device
IC-8 Apthera Intraocular Lens (IOL)
Acu Focus, Inc. · Extended Depth Of Focus Intraocular Lens (POE, Class III) · First FDA decision Jul 22, 2022, newest Jul 14, 2026Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
0
Naming "IC-8 Apthera"
MAUDE reports
58
Brand "IC-8 Apthera", since 2015
PubMed studies
7
Mentioning "IC-8 Apthera"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing IC-8 Apthera Intraocular Lens (IOL)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- IC-8 Apthera Intraocular Lens (IOL)PMA supplement
P210005-S010 · Decided Jul 14, 2026 · 431 days after receipt · Normal 180 Day Track No User Fee
Device type: Extended depth of focus intraocular lens (POE) · Ophthalmology
- IC-8 Apthera Intraocular Lens (IOL)PMA supplement
P210005-S007 · Decided Apr 25, 2025 · 140 days after receipt · Normal 180 Day Track No User Fee
Device type: Extended depth of focus intraocular lens (POE) · Ophthalmology
- IC-8 Apthera Intraocular LensPMA supplement
P210005-S005 · Decided Jul 31, 2023 · 60 days after receipt · Normal 180 Day Track No User Fee
Device type: Extended depth of focus intraocular lens (POE) · Ophthalmology
3 more FDA decisions with a free account
Older decisions: P210005
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "IC-8 Apthera", any status and sponsor, newest update first.
No registered device study names "IC-8 Apthera".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "IC-8 Apthera", and for the whole product code for context.
This brand
58 reports: 0 malfunction, 58 injury, 0 death
Whole product code POE
6,053 reports: 1,242 malfunction, 4,811 injury, 0 death
Newest reports for this brand
- IC-8 Apthera IOLInjury
0001313525-2026-00157 · Received Oct 19, 2026
Device type: Extended Depth Of Focus Intraocular Lens (POE)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Visual Impairment
- IC-8 Apthera IOLInjury
0001313525-2026-00122 · Received Aug 18, 2026
Device type: Extended Depth Of Focus Intraocular Lens (POE)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Blurred Vision; Halo
- IC-8 APTHERA IOLInjury
0001313525-2026-00044 · Received May 5, 2026 · Event dated Aug 27, 2024
Device type: Extended Depth Of Focus Intraocular Lens (POE)
Device problem as coded: Dent in Material
Patient problem as coded: Visual Impairment; Visual Disturbances; Halo
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "IC-8 Apthera"[tiab]. The summary above synthesizes these.
- AptheraTM Intraocular Lens in a Latino Population: A Case Series.
Santiago K, Izquierdo NJ, López-Fontanet JJ, et al. · Cureus · 2025
- Presbyopia intraocular lens in aberrated corneas.
Tay C, Mehta JS · Taiwan J Ophthalmol · 2025Review
- Incorrectly Focused Neodymium:Yttrium-Aluminum-Garnet (Nd:YAG) Laser Beam Leads to Massive Destructive Effects in Small-Aperture (Pinhole) Intraocular Lenses.
Borkenstein AF, Kormilina TK, Fitzek H, et al. · Ophthalmol Ther · 2024
- Predicted Visual Impact of a Small Aperture Intraocular Lens in Reducing Higher Order Aberrations in Post-Radial Keratotomy Patients.
van den Berg RM, DeVaro S, Rocha KM, et al. · Vision (Basel) · 2025
- Effects of Nd:YAG Capsulotomy on the IC-8 Lens.
Tay C, Mehta JS · J Refract Surg · 2026
- Carbon bursts inside a small aperture intraocular lens after Nd:YAG laser capsulotomy.
Bucur J, Werner L, Kohnen T · Am J Ophthalmol Case Rep · 2024Case Reports
- Visual Outcomes Following Cataract Surgery and Implantation of a Small-Aperture Intraocular Lens in Post-Refractive Surgery Patients.
Ang RET · Clin Ophthalmol · 2026Case Reports, Clinical Trial
Other devices of this type
Also filed under product code POE.
- TECNIS Symfony Extended Range Of Vision Intraocular LensJohnson & Johnson Surgical Vision, Inc. · PMA 2023
- Clareon Vivity Pro Extended Vision IOLsAlcon Laboratories, LLC · PMA 2026
- TECNIS Symfony PLUS Extended Range of Vision Intraocular Lens (IOL)Johnson & Johnson Surgical Vision, Inc. · PMA 2020
- AcrySof IQ Vivity Extended VisionAlcon Laboratories, Inc. · PMA 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.